This poster reviews results from a survey outlining the real-world experiences of patients being treated for type 2 diabetes using oral semaglutide (oral sema T2D), part of an effort to understand the patient's voice in healthcare. Information on patients’ demographic and clinical characteristics, T2D disease history and characteristics, and self-reported experiences with oral semaglutide, including TSQM09, and MATCH questionnaires as part of a long-standing collaboration between Novo Nordisk and Carelon (an Anthem company) were collected. All patients were part of US Medicare Advantage or commercial plans and study results included patient satisfaction, disease burden, caregiver status, and other measures regarding their care.